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Abstract
Background: The primary goal of asthma management is to achieve disease control for reducing the risk of future
exacerbations and progressive loss of lung function. Asthma not responding to treatment may result in significant
morbidity. In many children with uncontrolled symptoms, the diagnosis of asthma may be wrong or adherence to
treatment may be poor. It is then crucial to distinguish these cases from the truly “severe therapy-resistant” asthmatics
by a proper filtering process. Herein we report on four cases diagnosed as difficult asthma, detail the workup that resulted
in the ultimate diagnosis, and provide the process that led to the prescription of omalizumab.
Case presentation: All children had been initially referred because of asthma not responding to long-term treatment
with high-dose inhaled steroids, long-acting β2-agonists and leukotriene receptor antagonists. Definitive diagnosis was
severe asthma. Three out four patients were treated with omalizumab, which improved asthma control and patients’
quality of life. We reviewed the current literature on the diagnostic approach to the disease and on the comorbidities
associated with difficult asthma and presented the perspectives on omalizumab treatment in children and adolescents.
Based on the evidence from the literature review, we also proposed an algorithm for the diagnosis of pediatric difficult-
to-treat and severe asthma.
Conclusions: The management of asthma is becoming much more patient-specific, as more and more is learned about
the biology behind the development and progression of asthma. The addition of omalizumab, the first targeted
biological treatment approved for asthma, has led to renewed optimism in the management of children and adolescents
with atopic severe asthma.
Keywords: Severe asthma, Omalizumab, Children, Adolescents, Asthma exacerbations
Background
Children with poor asthma control have an increased risk
of severe exacerbations and progressive loss of lung func-
tion, which results in the relevant use of health resources
and impaired quality of life (QoL) [1]. Therefore, the pri-
mary goal of asthma management at all ages is to achieve
disease control [2–4].
According to recent international guidelines, patients
with uncontrolled asthma require a prolonged maintenance
treatment with high-dose inhaled corticosteroids (ICS) in
association with a long-acting β2-agonist (LABA) plus oral
leukotriene receptor antagonist (LTRA) (Table 1) [5].
Nevertheless, in the presence of persistent lack of con-
trol, reversible factors such as adherence to treatment or
inhalation technique should be first checked for, and
diseases that can masquerade as asthma should be
promptly excluded. Finally, additional strategies, in par-
ticular anti-immunoglobulin E (anti-IgE) treatment
(omalizumab), are suggested for patients with moderate
or severe allergic asthma that remains uncontrolled in
Step 4 [5].
Herein, we reviewed the demographics, clinical pres-
entation and treatment of four patients with uncon-
trolled severe asthma from our institution in order to
explain why we decided to prescribe omalizumab. We
also provided a review of the current literature that fo-
cuses on recent advances in the diagnosis of pediatric
difficult asthma and the associated comorbidities,
and summarizes the perspectives on anti-IgE treatment
in children and adolescents.
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Case presentations
Table 2 summarizes the clinical characteristics and the
triggers/comorbidities of the cases at referral to our
Institution. Unfortunately, data on psychological factors,
sleep apnea, and hyperventilation syndrome were not
available in any case. Clinical, lung function and airway
inflammation findings at baseline and after 12 months of
follow-up are reported in Table 3. In the description of
our cases, we used the terminology recommended by
the ERS/ATS guidelines on severe asthma [6].
Case 1
A full-term male had severe preschool wheezing and,
since age 3, recurrent, severe asthma exacerbations with
frequent hospital admissions. At age 11, severe asthma
was diagnosed. Sensitization to multiple inhalant aller-
gens (i.e., house dust mites, dog dander, Graminaceae
pollen mix, and Parietaria judaica) and high serum IgE
levels (1548 KU/l) were found. Body mass index (BMI)
was within normal range. Combined treatment with
increasing doses of ICS (fluticasone, up to 1000 μg/day)
in association with LABA (salmeterol, 100 μg/day) plus
LTRA (montelukast, 5 mg/day) has been administered
over 2 years. Nevertheless, persistent symptoms and
monthly hospital admissions due to asthma exacerba-
tions despite correct inhaler technique and good adher-
ence were reported. Parents refused to perform any test
to exclude gastroesophageal reflux (GER) as comorbidity
[6]. However, an ex-juvantibus 2-month-course with
omeprazole was added to asthma treatment [7], but poor
control persisted. Anterior rhinoscopy revealed rhinosi-
nusitis that was treated with nasal steroids for six
months [8], but asthma symptoms were unmodified.
Treatment with omalizumab was added at age 12.
Reduced hospital admissions for asthma exacerbations,
no further need for systemic steroids, and improved
QoL score (from 2.0 up to 6.7 out of a maximum of 7
points) were documented over the following months.
Unfortunately, after one year of treatment, adherence to
omalizumab decreased because of family complaints,
and eventually parents withdrew their informed consent
and discontinued omalizumab. Currently, by age 17,
treatment includes inhaled salmeterol/fluticasone
(100 μg/500 μg∙day-1, respectively) plus oral montelukast
(10 mg/day). Satisfactory symptom control is reported,
with no asthma exacerbations.
Table 1 Recommended options for initial controller treatment in children and adults according to GINA Guidelines [5]
Step 1 Step 2 Step 3 Step 4 Step 5
Preferred choice – Low dose ICS Low dose ICS/LABA Medium/high dose ICS/LABA Add anti-IgE
Alternative choices Low dose ICS LTRA Medium/high dose ICS Add tiotropium Add tiotropium
Low-dose theophylline Low dose ICS + LTRA High dose ICS + LTRA Add low dose OCS
Low dose ICS + theophylline High dose ICS + theophylline
Theophylline is not recommended for children 6–11 years, while tiotropium is not indicated in patients < 18 years
ICS inhaled corticosteroids, LTRA leukotriene receptor antagonist, LABA long-acting β2-agonist, anti-IgE anti-immunoglobulin E therapy, OCS oral corticosteroids
Table 2 Clinical characteristics of described patients with difficult asthma
Case 1 Case 2 Case 3 Case 4
Age at asthma symptoms onset 3 years 6 years 3 years 4 years
History Monthly asthma
exacerbations/
hospital admissions
Monthly asthma
exacerbations/
hospital admissions
Monthly asthma
exacerbations/
hospital admissions
Monthly asthma
exacerbations/
hospital admissions
Frequent need
of systemic steroids
Frequent need of
systemic steroids
Several ICU admissions Frequent need of
systemic steroids
Frequent need of
systemic steroids
Allergen sensitization House dust mites, dog
dander, Graminaceae pollen
mix, Parietaria judaica
House dust mites House dust mites, dog
and cat dander, Alternaria
alternata, Graminaceae
pollen mix, Artemisia vulgaris,
Parietaria judaica, Olea
europaea pollen, cow milk
proteins, egg, peanuts
House dust mites, dog
dander, Graminaceae
pollen mix, Olea europaea
pollen, tomatoes, beans,
shrimps, peas
Age at referral 11 years 10 years 6 years 8 years
Comorbidity Rhinosinusitis GER Absent Absent
Treatment at referral Fluticasone (1000 μg/d) +
salmeterol + montelukast
Fluticasone (1000 μg/d) +
salmeterol + montelukast
Fluticasone (1000 μg/d) +
salmeterol + montelukast
Fluticasone (1000 μg/d) +
salmeterol + montelukast
GER Gastroesophageal reflux, ICU Intensive care unit
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Case 2
A full-term male, who had a recurrent severe preschool
wheezing, at 6 years of age developed exercise-induced
asthma. At age 10, severe asthma was diagnosed. High
serum IgE levels (1300 KU/l) and skin prick tests posi-
tive to house dust mites were found. Despite a 3-year
treatment with progressively increasing doses of inhaled
fluticasone (up to 1000 μg/day) combined with salme-
terol (100 μg/day) and oral montelukast (5 mg/day),
monthly hospital admissions with systemic steroids use
were reported. At age 13, a 24-h esophageal impedance/
pH study demonstrated the presence of acid and non-
acid GER [7]. Esomeprazole was added to asthma medi-
cations, but with an incomplete clinical benefit for
respiratory symptoms. Esomeprazole was withdrawn
after 3 months, and parents refused to re-test for GER.
As respiratory symptoms persisted uncontrolled despite
treatment, severe asthma was definitively diagnosed [6].
BMI was within the normal range and anterior rhinos-
copy excluded rhinosinusitis. Inhaler technique and
adherence were good; thus we considered the anti-IgE
treatment option [9]. Subcutaneous omalizumab was
started, with fast improvement of both symptoms and
QoL score (from 3.9 up to 6.5). Seventeen months later,
the dose of ICS had been gradually tapered and oral
montelukast definitely discontinued. Currently, at age
14, treatment includes the combined administration of
bimonthly subcutaneous omalizumab and of daily
inhaled salmeterol/fluticasone (50 μg/100 μg∙day-1,
respectively). Asthma control is satisfactory and no side
effects are reported. Omalizumab has been continuously
administered for 2.6 years and is still ongoing.
Case 3
A full-term male had severe preschool wheezing and,
since age 3, recurrent, severe asthma exacerbations with
acute respiratory failure that frequently required intensive
care unit (ICU) admission. At age 6, sensitization to mul-
tiple perennial inhalant (i.e., house dust mites, dog and cat
danders, Alternaria alternata, Graminaceae pollen mix,
Artemisia vulgaris, Parietaria judaica, and Olea europaea
pollen) and food allergens (i.e., egg, milk, and peanut) was
diagnosed. Serum IgE levels were 2219 KU/l. Weight and
height were appropriate for age and sex. The patient has
been treated over 3 years with a combined scheme of
high-dose inhaled fluticasone (up to 1000 μg/day) plus
salmeterol (100 μg/day) and oral montelukast (5 mg/day),
with correct inhaler technique and good adherence. Des-
pite this, monthly hospital admissions with systemic
steroids use were recorded. Rhinosinusitis and GER were
excluded on the basis of appropriate testing; thus treat-
ment with omalizumab was started when the patient was
9 years old. At age 11, adherence to treatment is satisfac-
tory, with no side effects. More importantly, reduced
hospital admissions for asthma exacerbations, no further
need for systemic steroids, and improved QoL score (from
6.4 to 6.8) were reported. Finally, progressive step-down
of anti-asthma treatment was started, and at present (by
11.5 years) inhaled fluticasone (200 μg/day) plus
bimonthly subcutaneous omalizumab provide good con-
trol of symptoms. Omalizumab has been continuously
administered for 2.6 years and is still ongoing.
Case 4
A full-term male had severe preschool wheezing and, since
age 4, recurrent, severe asthma exacerbations with frequent
hospital admissions. At age 8, multiple perennial inhalants
and food sensitization (i.e., house dust mites, dog dander,
Graminaceae pollen mix, Olea europaea pollen, tomatoes,
beans, shrimps, and peas) and high serum IgE levels (1166
KU/l) were found. The patient has been treated over 5 years
with inhaled fluticasone (up to 1000 μg/day) in association
Table 3 Clinical findings at baseline and after 12 months of follow-up in patients with difficult asthma
Case 1 Case 2 Case 3 Case 4
Baseline T 12 months Baseline T 12 months Baseline T 12 months Baseline T 12 months
FVC (% pred) 109 127 95 97 98 95 103 113
FEV1 (% pred) 80 78 74 85 67 94 90 85
Post BD ΔFEV1 (%) 3 NA 7 NA 25 NA 12.1 NA
FEV1/FVC (%) 64 87 69 73 67 82 70 66
FEF25–75 (% pred) 14 61 41 55 25 72 48 46
Post BD ΔFEF25–75 (%) 21 NA 8 NA 55 NA 69 NA
FeNO (ppb) 54 21 19 7 36 5 116 NA
QoL score 2.0 6.7 3.9 6.5 6.4 6.8 4.0 5.9
c-ACT Score 17 23 22 25 17 21 12 15
Current treatment Fluticasone (500 μg/d) +
salmeterol + montelukast
Fluticasone (100 μg/d) +
salmeterol + omalizumab
Fluticasone (200 μg/d) +
montelukast + omalizumab
Fluticasone (1000 μg/d) +
salmeterol + montelukast
BD bronchodilator, Δ % predicted changes from the pre-bronchodilator values, FeNO fractional exhaled nitric oxide, Ppb part per billion, QoL Quality of Life defined
according to references [14], c-ACT Children Asthma Control Test evaluated according to references [79, 80], NA Not Available
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with salmeterol (100 μg/day) and oral montelukast (5 mg/
day). Despite this, monthly hospital admissions with
systemic steroids need were recorded. After checking the
inhaler technique and adherence to treatment, comorbidi-
ties including obesity, rhinosinusitis and GER were
excluded. Omalizumab was proposed, but parents refused
it. By 13.6 years, despite a treatment including the
association of inhaled salmeterol/fluticasone (100 μg/
1000 μg∙day− 1, respectively) plus oral montelukast (10 mg/
day), monthly exacerbations requiring systemic steroids are
reported.
Discussion and conclusions
Most children and adolescents with asthma respond well
to inhaled short-acting beta2-agonists (SABA) on demand
if symptoms are intermittent, or to low dose controller
drugs plus as-needed SABA if the risk of exacerbations
increases [1]. Nevertheless, a proportion of patients is
referred to specialists because this strategy is not working
and asthma is persistently uncontrolled [4]. For these
children, assessment is primarily aimed at investigating
the reasons for poor control. Indeed, when the child is ini-
tially referred, before the label of “severe, therapy-resistant
asthma” (i.e., not responding to treatment even when
factors as exposure to allergens and tobacco smoke have
been considered) is assigned, three main categories need
to be identified: 1) “not asthma at all”, in which response
to treatment is suboptimal because the diagnosis is wrong;
2) “asthma plus”, when asthma is mild but exacerbated by
one or more comorbidities; and 3) “difficult-to-treat
asthma”, when asthma is uncontrolled because of poten-
tially reversible factors [10].
The reported cases highlight some aspects of the disease
process that may expand the diagnosis and improve
patients’ care. At our institution, the severe asthma
program includes a multidisciplinary approach with con-
sultations by gastroenterologists as well as ear, nose and
throat experts. Recently, sleep medicine experts joined this
multidisciplinary team; thus, unfortunately, sleep-
disordered breathing (SDB) could not be excluded at the
time of our patients’ assessment. Inhalation technique is
periodically evaluated by nurses or doctors in each patient.
Unfortunately, in Italy an individual prescription database
is not available and thus we cannot assess patients’ use of
medication. In two cases, the filtering process eventually
identified GER and rhinosinusitis, but poor control of
asthma persisted even after comorbidities were treated. In
all subjects, inhaler skills, treatment adherence, and envir-
onmental exposure to indoor/outdoor allergens as well as
to second- and third-hand smoke were excluded as cause
of lack of control. Eventually, three out of four patients
started anti-IgE treatment; asthma control was obtained
and maintenance drugs were progressively reduced. In the
case that refused omalizumab therapy, pulmonary
function, clinical features and controller treatment includ-
ing high-dose ICS were unchanged.
Previous studies have highlighted an association
between increasing asthma severity in children and
reduced QoL [11–13]. Uncontrolled asthma symptoms
not only affect children physically, but can impair them
socially, emotionally, and educationally [13]. In line with
previous observations, 3 out 4 of our cases had poor QoL,
assessed by a standardized questionnaire [14]. It is well
known that improving QoL in difficult asthma is not an
easy task, despite a variety of treatments aimed at achiev-
ing control [12], and much more remains to be done to
address the problem. Nevertheless, 2 of our 3 cases
showed a remarkable improvement of QoL after one year
of treatment with omalizumab.
Reduction in forced expiratory volume in the first sec-
ond (FEV1) is often used to define childhood asthma se-
verity in treatment guidelines and clinical studies [5, 11,
15]. Nevertheless, children with severe asthma often have
a normal FEV1 that does not improve after bronchodila-
tors, indicating that spirometry may be a poor predictor of
asthma severity in childhood [6, 16, 17]. Actually, children
with a normal FEV1, both before and after β2-agonist, may
show a bronchodilator response in terms of forced expira-
tory flow between 25% and 75% (FEF25–75) [18]. However,
the utility of FEF25–75 in the assessment or treatment of
severe asthma is currently unknown. Interestingly, all the
reported cases showed normal or slightly reduced values
of FEV1 but severe impairment of FEF25–75. Two cases
showed a bronchodilator response in terms of FEV1 (sub-
jects 3 and 4), while 3 patients had a significant increase
of FEF25–75 (cases 1, 3 and 4). Unfortunately, we could not
provide the results of bronchodilator response during or
after the treatment with omalizumab in any case.
Available literature on the diagnostic approach to difficult
asthma in children offers a number of reviews which basic-
ally summarize the steps needed to fill the gap between a
generic diagnosis of “difficult asthma” and more specific la-
bels (i.e., “severe” asthma, “difficult-to-treat” asthma, or
even different diagnoses) [3, 5, 6, 8, 10, 19–21]. So far, few
original articles and case reports have been published, prob-
ably due to the peculiarity of the issue, which makes retro-
spective discussion of cases easier than the design of a
prospective clinical study [4, 22–26]. Available knowledge
mainly derives from the experience of specialized centers.
The evaluation of a child referred for uncontrolled
asthma should start with a careful history focused on typ-
ical respiratory symptoms and on the definition of possible
triggers. In the “severe asthma” process, it is crucial for
clinicians to maintain a high degree of skepticism about
the ultimate diagnosis, particularly in the presence of rele-
vant discrepancies between history, physical features and
lung function, as many conditions may be misdiagnosed
as asthma. In order to simplify this process, herein we
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propose an algorithm for the diagnosis of difficult-to-treat
and severe asthma (Fig. 1). Confirmation of the diagnosis
through a detailed clinical and laboratory re-evaluation is
important because in 12–50% of cases assumed to have
severe asthma this might not be the correct diagnosis [10].
Several documents have indicated the main steps of the
process that should be followed in children with uncon-
trolled asthma [3, 8, 10]. The translation of these proce-
dures into real life practice may deeply change from one
subject to another due to the variability of individual
patients’ history and clinical features, which will often lead
the diagnostic investigations towards the most likely rea-
son for uncontrolled asthma. For children with apparently
severe asthma, the first step is to confirm the diagnosis
and, before proceeding to broader investigations, to verify
that the poor control is not simply determined by poor
adherence to treatment, inadequate inhaler skills and/or
environmental exposure to triggers. A nurse-led assess-
ment, including a home visit, despite not being applicable
in all settings, may be useful for identifying potentially
modifiable factors in uncontrolled pediatric asthma [27].
A number of comorbidities have been increasingly
recognized as factors that may impact asthma clinical
expression and control in childhood [10, 28]. Children with
uncontrolled disease should be investigated for GER, rhino-
sinusitis, dysfunctional breathing and/or vocal cord dys-
function, obstructive sleep apnea, obesity, psychological
factors, smoke exposure, hormonal influences, and ongoing
drugs [3, 6, 8, 20]. Indeed, the exact role played by comor-
bidities in pediatric asthma control is still debated [28]. The
most impressive example is GER. Several pediatric docu-
ments recommend assessing for GER because reflux may
be a contributing factor to problematic or difficult asthma
[7, 29]. Nevertheless, GER treatment might not be effective
for severe asthma [30, 31], as confirmed by current cases 1
and 2. There is an established evidence that chronic rhino-
sinusitis is associated with more severe asthma in children
[32–34]. Therefore, examination of upper airways and ad
hoc treatment if rhinosinusitis is evident are recom-
mended in children with severe asthma [3, 8, 35]. How-
ever, intranasal steroids for rhinitis resulted in a small
reduction of asthma risk in school-aged children [36], and
actual placebo-controlled studies on the effect of treat-
ment of rhinosinusitis on asthma control in children are
lacking [10, 37].
Dysfunctional breathing, including hyperventilation and
vocal cord dysfunction, is associated with poorer asthma
control in children [8, 10, 38, 39]. Unfortunately, there is
scarce literature on the effect of its treatment on the con-
trol of severe asthma in children [40]. SDB ranging from
primary snoring to obstructive sleep apnea syndrome is
very common in children [41], and an increased preva-
lence of SDB together with increasing asthma severity has
been reported [42]. Interestingly, GER may also be wors-
ened by recurrent episodes of upper airway obstruction
associated with SDB, and this may further trigger bron-
chial obstruction. Asthma guidelines recommend the as-
sessment of SDB through nocturnal polysomnography in
poorly controlled asthmatics, particularly if they are also
obese [5]. There are no studies examining whether
pediatric asthma improves after SDB has been treated, for
example, with nasal steroids, adenotonsillectomy, continu-
ous positive airway pressure or weight reduction if the
child is also obese [43]. The parallel increase in obesity
and asthma suggests that the two conditions are linked
and that they can aggravate each other [44, 45], even
though the exact mechanisms that underlie this associ-
ation remain unclear [46]. Indeed, other coexisting comor-
bidities such as SDB or GER may play a confounding role
in the development of the interactions between obesity and
the airways [47, 48]. Obesity is associated with increased
markers of inflammation in serum and adipose tissue and
yet decreased airway inflammation in obese people with
asthma [49]. Several interventions, including behavioral and
Fig. 1 A practical algorithm for the diagnosis of difficult-to-treat and severe asthma. ICS, inhaled corticosteroids; OCS, oral corticosteroids
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weight reduction programs or bariatric surgery, may result
in improved asthma control, quality of life and lung func-
tion in adult obese asthmatics [50]. Although reports of
adolescent bariatric surgery demonstrate a significant body
weight decrease, this approach is not widely available and
there are no published reports on its effect on pediatric se-
vere asthma control [51]. Finally, although it is still unclear
whether food allergy is causative or shares a common path-
way with difficult asthma, it might explain the loss of
asthma control at least in some children and thus be con-
sidered as a comorbid condition [10, 16, 52].
In conclusion, establishing the impact of comorbidities on
asthma control may be cumbersome, and an ex-juvantibus
treatment is sometimes necessary to assess their role.
Comorbid conditions can also worsen each other, and symp-
toms arising from some of them may mimic asthma [6].
Although the ability to improve pediatric severe asthma by
treating comorbidities remains unconfirmed, they should be
treated appropriately [9].
The vast majority of asthmatic children exhibit a mild
or at most a moderate disease that can be fully controlled
with low-to-medium dose ICS associated or not with
other controllers [5, 6]. However, a subset of asthmatics
remains difficult-to-treat [5, 6]. With the advent of bio-
logics, these severe steroid-dependent asthmatics have
alternative options for treatment, as steroid-related
adverse events are common in severe asthma [53].
Omalizumab, an anti-IgE monoclonal antibody, is the only
biologic therapy recommended in children with
moderate-to-severe asthma by the recent guidelines [5, 6].
In Italy, this treatment is fully covered by the National
Health System. Therefore, there is no influence by any
funding on treatment decisions. It was approved by the
US (Food and Drug Administration) in 2003 and by the
European Union (European Medicines Agency) in 2005 as
an add-on treatment for patients aged > 12 years with
severe persistent allergic asthma and who have a
positive skin test or in-vitro reactivity to a perennial
aeroallergen, FEV1 < 80% predicted, frequent daytime
symptoms or nighttime awakenings, and multiple docu-
mented severe asthma exacerbations despite daily ICS
plus a LABA [54, 55]. In 2009, it also received approval
in Europe for treating patients aged 6–12 years. Figure 2
illustrates current indications for treatment with omali-
zumab in children and adolescents with severe asthma.
IgE antibodies, Th2-derived cytokines and eosinophils
play a major role in the development of chronic airway
inflammation in asthmatic subjects [56]. Once released
from plasma cells, IgE binds principally to the high-
affinity IgE receptor (FcεRI) on mast cells, triggering
Fig. 2 Indications for omalizumab in children and adolescents with severe asthma
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different effector responses, including the release of medi-
ators leading to allergic inflammatory reactions [56]. The
activation of the allergic cascade by IgE, under constant
allergen stimulation, leads to the establishment of chronic
allergic inflammation in the airways of asthmatic patients,
with IgE being a key element of the vicious circle that
maintains it. Cytokines produced during the late phase
and subsequent chronic inflammation stage have been
directly associated with the induction of airway remodel-
ling, indirectly implicating IgE in the process [56]. At
present, omalizumab is the only commercially available
recombinant humanized anti-IgE monoclonal antibody
that specifically binds serum free IgE at its CH3 domain,
in the proximity of the binding site for FcεRI, thus pre-
venting IgE from interacting with its receptor on mast
cells, basophils, antigen-presenting cells and other inflam-
matory cells [57]. The rapid reduction of free IgE levels
leads to a downregulation of the FcεRI expression on
inflammatory cells and an interruption of the allergic
cascade, which results in the reduction of peripheral and
bronchial tissue eosinophilia and of levels of granulocyte
macrophage colony stimulating factor, interleukin (IL)-2,
IL-4, IL-5, and IL-13 [58]. Moreover, basophils have a rele-
vant role in the initiation and progression of allergic
inflammation, suggesting that they may represent a viable
therapeutic target. Indeed, in children with severe asthma,
it has been reported that omalizumab therapy is associated
with a significant reduction in circulating basophil num-
bers, a finding that is concurrent with improved clinical
outcomes [59]. This finding supports a mechanistic link
between IgE levels and circulating basophil populations,
and may provide new insights into one mechanism by
which omalizumab improves asthma symptoms.
Several clinical controlled and real-life studies of adults
with severe, inadequately controlled allergic asthma have
demonstrated the efficacy and safety of omalizumab in
reducing asthma-related symptoms, corticosteroid use,
exacerbation rates, and healthcare resource utilization,
and in improving QoL and lung function [60–63]. Fewer
studies have been published in children. In two double-
blind, randomized, placebo-controlled trials (RCTs) of
children aged 6 to 12 years with moderate-to-severe aller-
gic asthma, treatment with omalizumab reduced the
requirement for ICS and protected against disease exacer-
bations, but there was little change in asthma symptom
scores or spirometry [9, 64]. These findings were con-
firmed and extended in older children [65–67].
The results of the ICATA study, a multicenter RCT of
419 inner-city children, adolescents and young adults with
persistent allergic asthma, showed that, compared to
placebo, omalizumab reduces the number of days with
asthma symptoms and the proportion of participants with
at least one exacerbation by approximately 25% and 19%,
respectively (p < 0.001), thus reducing the need for
asthmatic symptom controllers [68]. Another multicenter
RCT of inner-city children and adolescents showed that
the addition of omalizumab to ongoing guidelines-based
care before patients return to school reduces fall asthma
exacerbations (odds ratio, 0.48), particularly in subjects
with a recent exacerbation [69]. Moreover, in a real-life
study of 104 children and adolescents with severe allergic
refractory asthma followed over 1 year, treatment with
omalizumab resulted in good asthma control in 67% of the
cases (p < 0.001), while FEV1 improved by 4.9% (p = 0.02)
and exacerbation rates and healthcare utilisation decreased
approximately by 30% (p < 0.001) [70]. The same authors
also showed that, after two years of treatment, exacerbation
rate and healthcare utilisation were further decreased by
83% and 100%, respectively, while level of asthma control,
steroid use and lung function remained unchanged [71].
A systematic review of pediatric RCTs pooled the
data of 1381 children and adolescents with moderate-
to-severe allergic asthma in order to establish the
efficacy of omalizumab as an add-on therapy [72].
During the stable-steroid phase, omalizumab
decreased the number of patients with at least one
exacerbation (risk ratio, 0.69; p < 0.001), the mean
number of asthma exacerbations per patient (risk
ratio, 0.35; p < 0.001), and the asthma symptom score
(mean difference, 0.12; p = 0.005) when compared to
placebo. During the steroid reduction phase, omalizu-
mab further reduced the number of patients with at
least one exacerbation (risk ratio, 0.48; p < 0.001) and
the mean number of asthma exacerbations per patient
(mean difference, 0.12; p < 0.05).
Given the cost of omalizumab, many authors have argued
for the importance of identifying specific asthma popula-
tions who will have significant benefit from it [68, 73, 74].
In the ICATA study, baseline predictors of good response
to treatment were sensitization and exposure to cockroach
allergen, sensitization to house dust mite allergens, a serum
IgE level of more than 100 IU per milliliter, a BMI of 25 or
more, and a history of at least one unscheduled medical
visit in the previous year [68].
Several studies have assessed the long-term safety of
omalizumab in children and adults. A pooled analysis
of 67 RCTs conducted over 2 decades on 4254
children and adults treated with omalizumab showed
no association between omalizumab treatment and
risk of malignancy [75]. In an RCT evaluating 225
school-aged children, omalizumab was well tolerated,
there were no serious adverse events, and the fre-
quency and types of all adverse events were similar to
the placebo group [9]. These results have been further
confirmed by a recent systematic review of RCTs that
concluded that treatment with omalizumab does not
result in increased risk of malignancy or hypersensi-
tivity reactions [72].
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While the rationale for long-term treatment with omali-
zumab is supported by pharmacokinetic-pharmacodynamic
models [76], the duration of treatment is still under
discussion. Results from published studies suggest that
omalizumab should be continued for > 1 year [77, 78]. In a
retrospective study of adults and children with uncontrolled
severe asthma treated with omalizumab, the response to
treatment was ‘excellent’ in 52.5% of patients, particularly
in the subgroup of children aged 6 to 11 years [77]. After
the discontinuation of treatment, loss of asthma control
was documented in 69.2% of the patients who had received
omalizumab for < 1 year, 59.1% of the subjects treated for
1–2 years, and 46.1% of the cases treated for > 2 years.
Time to loss of control was shorter in younger children and
longer in patients with an ‘excellent’ response compared
with patients with a ‘good’ response. No early loss of con-
trol (within 6 months) was observed among patients with
> 3.5 years of continuous treatment with omalizumab.
Finally, 20% of patients in whom omalizumab was re-
prescribed because of loss of control did not respond to the
treatment anymore [77]. Despite these encouraging find-
ings, the impact of omalizumab on the natural history of
severe asthma in children deserves to be further investi-
gated by long-term studies that will also define the criteria
and timing for discontinuing the treatment.
It is well known that asthma pharmacotherapy is effect-
ive in controlling symptoms and bronchial inflammation,
but cannot affect the underlying immune response, thus
leading to the possibility of symptom reappearance after
its discontinuation [79]. In this scenario, allergen-specific
immunotherapy (AIT) has been proposed as the only
therapeutic method that can modulate the underlying
immune pathophysiology in allergic asthma [80].
AIT is currently indicated in children and adults with
mild-moderate allergic asthma that is completely or par-
tially controlled by pharmacotherapy and with the evidence
of a clear relationship between symptoms and exposure to
a specific allergen [81–84]. However, according to recent
guidelines, the efficacy of AIT in asthmatic subjects is
limited, and its potential benefits must be weighed against
the risk of side effects and the inconvenience and costs of
the prolonged therapy [5]. Moreover, severe or uncon-
trolled asthma (regardless of its severity) is a major inde-
pendent risk factor for non-fatal or even fatal adverse
reactions, thus representing a contraindication for AIT
[85–87]. Finally, children with severe asthma are often
sensitized to multiple allergens, thus making AIT prescrip-
tion even more complicated [88].
In subjects with uncontrolled and/or severe allergic
asthma, a combination of omalizumab and AIT has been
proposed [88]. Surprisingly, only a few studies have
addressed this issue [89–92]. However, pre-treatment with
omalizumab seems to improve the efficacy and tolerability
of subcutaneous AIT in children and adults with severe
allergic asthma both during omalizumab treatment and
after its discontinuation [89, 91, 92]. Omalizumab has also
been successfully used as a supplementary treatment to
AIT in order to improve asthma control in children ≥6 years
with severe persistent allergic asthma [90]. Given the scar-
city of studies on AIT plus omalizumab in children with
severe allergic asthma, further research is warranted to
assess risks and benefits of the combined treatment.
Children with severe asthma require a detailed and indi-
vidualized approach including re-assessment for differential
diagnoses, comorbidities and contributory factors, environ-
mental triggers, lung function and inflammation, adherence
and response to therapy, and QoL. Treatment of pediatric
severe asthma still relies on the maximal optimal use of
corticosteroids, bronchodilators and other controllers rec-
ommended for moderate-to-severe disease. However, the
management of asthma is becoming much more patient-
specific, as more and more is learned about the biology
behind the development and progression of asthma.
In the current paper, we described the characteristics of
four children with severe asthma in whom omalizumab
was prescribed. A review of the relevant literature on the
topic was also performed. Finally, we provided an algorithm
for the diagnosis of difficult-to-treat and severe asthma in
children and adolescents, based on the evidence from the
literature review. As all algorithms, it is not meant to
replace clinical judgment, but it should drive physicians to
adopt a systematic approach towards difficult and severe
asthma and provide a useful guide to the clinician.
The addition of omalizumab, the first targeted biological
treatment approved for asthma, has led to renewed opti-
mism of outcome improvements in patients with allergic
severe asthma. As severe asthma is a heterogeneous con-
dition consisting of different phenotypes, the future of
asthma management will likely involve phenotypic and
potentially even genotypic characterization in selected
cases in order to determine appropriate therapy and thus
to provide the highest possible benefit, especially if specific
responder phenotypes can be identified and selected for
this highly specific treatment.
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